Hospital
Sierra Vista Hospital
Sierra Vista Hospital was paid $15.48M by Medicaid between Jan 2018 and Dec 2024, across 137 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoSIERRA VISTA HOSPITAL
TRUTH OR CONSEQUENCES, NM 87901
TRUTH OR CONSEQUENCES, NM 87901
33aNPI1760446009assigned 04/13/2006
33bProvider typeCritical Access Hospital
28Total paid$15.48M
24GClaims157,845
24DCodes billed137
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in New Mexico
Rank by total paid#4 of 6
Median peer was paid$15.48M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,971 | $2.44M | |
| 2019 | 16,964 | $1.71M | |
| 2020 | 14,404 | $1.31M | |
| 2021 | 22,403 | $1.83M | |
| 2022 | 25,397 | $2.48M | |
| 2023 | 30,554 | $2.92M | |
| 2024incomplete | 23,152 | $2.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 10,708 | 9,929 | $3.70M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 4,800 | 4,393 | $1.93M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.5% | 2,938 | 2,628 | $1.47M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.6% | 1,045 | 889 | $869K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.5% | 1,959 | 1,454 | $703K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.1% | 3,973 | 3,501 | $485K |
| 80053 | Comprehensive metabolic panel | 2.9% | 12,995 | 10,881 | $446K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 4,997 | 4,300 | $407K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.6% | 3,974 | 3,138 | $398K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 1,524 | 1,483 | $349K |
| G0390 | Trauma response team associated with hospital critical care service | 2.2% | 1,011 | 972 | $339K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 573 | 459 | $304K |
125 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.7% | 1,740 | $259K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 1,424 | $244K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 3,146 | $243K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 3,326 | $236K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 2,711 | $224K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 13,821 | $221K |
| A0425 | Ground mileage, per statute mile | 1.2% | 1,831 | $189K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.2% | 4,526 | $182K |
| A0427 | Emergency ambulance ride, advanced life support | 1.1% | 432 | $163K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,984 | $152K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 432 | $151K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 307 | $127K |
| 84484 | <1% | 4,141 | $106K | |
| 83880 | <1% | 2,115 | $87K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,520 | $86K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 494 | $75K |
| G0378 | Hospital observation service, per hour | <1% | 162 | $74K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 426 | $59K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,969 | $53K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 95 | $50K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,230 | $48K |
| 80320 | <1% | 955 | $48K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 805 | $48K |
| 83690 | <1% | 2,210 | $45K | |
| 80305 | <1% | 1,344 | $45K | |
| 71250 | <1% | 135 | $41K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 194 | $41K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 309 | $41K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 193 | $41K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 57 | $40K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,013 | $39K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 477 | $39K |
| 85730 | <1% | 1,475 | $36K | |
| 80061 | Lipid panel | <1% | 1,476 | $32K |
| 81001 | <1% | 2,764 | $32K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 776 | $31K |
| 80050 | General health panel | <1% | 270 | $25K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,592 | $22K |
| 85610 | <1% | 2,387 | $21K | |
| 96376 | <1% | 344 | $16K | |
| A9270 | Non-covered item or service | <1% | 5,069 | $16K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 148 | $16K |
| 81003 | <1% | 2,058 | $15K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 325 | $14K |
| 86710 | <1% | 362 | $14K | |
| 91301 | <1% | 412 | $13K | |
| 83735 | <1% | 950 | $12K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 365 | $12K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 12 | $11K |
| 83605 | <1% | 452 | $11K | |
| 86140 | <1% | 1,490 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 639 | $11K |
| 81025 | <1% | 533 | $10K | |
| 73562 | <1% | 65 | $10K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 607 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,339 | $9K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 89 | $9K |
| 82553 | <1% | 430 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 109 | $7K |
| 0012A | <1% | 178 | $7K | |
| 82550 | <1% | 497 | $7K | |
| 73030 | <1% | 30 | $7K | |
| 0002A | <1% | 126 | $5K | |
| 99441 | <1% | 95 | $5K | |
| 0011A | <1% | 202 | $5K | |
| 91300 | <1% | 393 | $5K | |
| 87807 | <1% | 125 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 65 | $5K |
| 87650 | <1% | 92 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 45 | $4K |
| 87077 | <1% | 224 | $4K | |
| 87088 | <1% | 254 | $4K | |
| 73630 | <1% | 29 | $4K | |
| 82607 | <1% | 177 | $4K | |
| 87186 | <1% | 185 | $3K | |
| 0001A | <1% | 131 | $3K | |
| 84439 | <1% | 170 | $3K | |
| 87040 | <1% | 125 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 15 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 56 | $3K |
| 84703 | <1% | 108 | $3K | |
| 85379 | <1% | 72 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,807 | $3K |
| 76770 | <1% | 15 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 36 | $3K |
| 76536 | <1% | 16 | $3K | |
| 0003A | <1% | 31 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 36 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,359 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,063 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 25 | $2K |
| 85651 | <1% | 173 | $2K | |
| 90837 | Psychotherapy session, about an hour | <1% | 22 | $2K |
| 51702 | <1% | 14 | $1K | |
| 87641 | <1% | 46 | $1K | |
| 82043 | <1% | 130 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 735 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 57 | $1K |
| 85027 | <1% | 63 | $989.45 | |
| 0124A | <1% | 13 | $795.37 | |
| 82150 | <1% | 47 | $777.87 | |
| 80143 | <1% | 16 | $728.80 | |
| 83550 | <1% | 45 | $653.37 | |
| 82728 | <1% | 12 | $445.42 | |
| 83540 | <1% | 44 | $387.50 | |
| 84481 | <1% | 13 | $352.76 | |
| 87070 | <1% | 15 | $331.48 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 45 | $265.09 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 209 | $210.31 |
| 87081 | <1% | 18 | $210.00 | |
| 85652 | <1% | 25 | $207.56 | |
| 82746 | <1% | 12 | $136.15 | |
| 82570 | <1% | 13 | $135.15 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 73 | $86.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 71 | $71.37 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 172 | $65.82 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 97 | $58.07 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 119 | $56.56 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 122 | $53.58 |
| J3490 | Unclassified drugs | <1% | 13 | $46.77 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 13 | $22.51 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 16 | $20.06 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 16 | $5.03 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFAULKNER, DAVID (INTERIM CEO)
| Provider | Location | Paid |
|---|---|---|
| Sierra Vista Hospital | Truth Or Consequences, NM | $2.62M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.